On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
BUSINESS
BMS Files to Fully Localize Breyanzi Production in Japan
Bristol Myers Squibb has filed for a partial change to its Japanese regulatory approval to enable full domestic production of its CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) in Japan, the company said on April 7. Under the plan, Nikon Cell…
To read the full story
Related Article
- BMS, Nikon Pitch Japan-to-Asia Cell Therapy Push, Draw Support at Policy Forum
May 21, 2026
- BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
March 19, 2026
- Nikon Bets 10 Billion Yen on Regenerative Medicine CDMO Push
September 22, 2025
- BMS Mulls CAR-T Manufacturing in Japan, Definitive Plans Expected by Year-End
February 14, 2023
BUSINESS
- MSD Set to Match Beyfortus Price for RSV Antibody Enflonsia if Added to NIP
November 12, 2026
- Takeda Files Zasocitinib for Three Psoriasis Indications in Japan
November 12, 2026
- Japan Approves Fujirebio’s Blood-Based pTau217 Test for Alzheimer’s
November 12, 2026
- Japan Pharma Market Put at 13 Trillion Yen in FY2031, Growth to Slow: IQVIA
November 11, 2026
- Eisai Nets Double-Digit Sales, Profit Growth on Core Products, Weak Yen
November 11, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…